These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31217199)

  • 1. Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas).
    Sanfilippo R; Jones RL; Blay JY; Le Cesne A; Provenzano S; Antoniou G; Mir O; Fucà G; Fumagalli E; Bertulli R; Stacchiotti S; Brahmi M; Grosso F; Dufresne A; Hindi N; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG
    Clin Cancer Res; 2019 Sep; 25(17):5295-5300. PubMed ID: 31217199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.
    Frezza AM; Jones RL; Lo Vullo S; Asano N; Lucibello F; Ben-Ami E; Ratan R; Teterycz P; Boye K; Brahmi M; Palmerini E; Fedenko A; Vincenzi B; Brunello A; Desar IME; Benjamin RS; Blay JY; Broto JM; Casali PG; Gelderblom H; Grignani G; Gronchi A; Hall KS; Mir O; Rutkowski P; Wagner AJ; Anurova O; Collini P; Dei Tos AP; Flucke U; Hornick JL; Lobmaier I; Philippe T; Picci P; Ranchere D; Renne SL; Sbaraglia M; Thway K; Wagrodzki M; Wang WL; Yoshida A; Mariani L; Kawai A; Stacchiotti S
    JAMA Oncol; 2018 Sep; 4(9):e180219. PubMed ID: 29800950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors.
    Sanfilippo R; Fabbroni C; Fucà G; Fumagalli E; Morosi C; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG
    Clin Cancer Res; 2020 Oct; 26(20):5534-5538. PubMed ID: 32605908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.
    Frezza AM; Assi T; Lo Vullo S; Ben-Ami E; Dufresne A; Yonemori K; Noguchi E; Siontis B; Ferraro R; Teterycz P; Duffaud F; Ravi V; Vincenzi B; Gelderblom H; Pantaleo MA; Baldi GG; Desar I; Fedenko A; Maki RG; Jones RL; Benjamin RS; Blay JY; Kawai A; Gounder M; Gronchi A; Le Cesne A; Mir O; Czarnecka AM; Schuetze S; Wagner AJ; Adam J; Barisella M; Sbaraglia M; Hornick JL; Meurgey A; Mariani L; Casali PG; Thornton K; Stacchiotti S
    Cancer; 2020 Jan; 126(1):98-104. PubMed ID: 31536651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-institution Retrospective Analysis.
    Testa S; Bui NQ; Ganjoo KN
    Cancer Res Commun; 2023 Jul; 3(7):1212-1223. PubMed ID: 37448552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report.
    Meredith L; Chao T; Nevler A; Basu Mallick A; Singla RK; McCue PA; Bowne WB; Jiang W
    Diagn Pathol; 2023 Apr; 18(1):45. PubMed ID: 37041531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates.
    Dickson MA; Schwartz GK; Antonescu CR; Kwiatkowski DJ; Malinowska IA
    Int J Cancer; 2013 Apr; 132(7):1711-7. PubMed ID: 22927055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical treatment of advanced malignant perivascular epithelioid cell tumors.
    Fabbroni C; Sbaraglia M; Sanfilippo R
    Curr Opin Oncol; 2020 Jul; 32(4):301-306. PubMed ID: 32541317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.
    Gao F; Huang C; Zhang Y; Sun R; Zhang Y; Wang H; Zhang S
    Cancer Biol Ther; 2016 Jun; 17(6):595-8. PubMed ID: 27030639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
    Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
    Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature.
    Starbuck KD; Drake RD; Budd GT; Rose PG
    Anticancer Res; 2016 Nov; 36(11):6161-6164. PubMed ID: 27793946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma.
    Gounder MM; Merriam P; Ratan R; Patel SR; Chugh R; Villalobos VM; Thornton M; Van Tine BA; Abdelhamid AH; Whalen J; Yang J; Rajarethinam A; Duh MS; Bobbili PJ; Huynh L; Totev TI; Lax AK; Agarwal S; Demetri GD
    Cancer; 2021 Apr; 127(8):1311-1317. PubMed ID: 33296083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
    Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG
    J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant PEComa With Metastatic Disease at Diagnosis and Resistance to Several Chemotherapy Regimens and Targeted Therapy (m-TOR Inhibitor).
    Machado I; Cruz J; Lavernia J; Rayon JM; Poveda A; Llombart-Bosch A
    Int J Surg Pathol; 2017 Sep; 25(6):543-549. PubMed ID: 28459168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gynecologic perivascular epithelioid cell tumors (PEComas): a review of recent evidence.
    Levin G; Capella MP; Meyer R; Brezinov Y; Gotlieb WH
    Arch Gynecol Obstet; 2024 Jun; 309(6):2381-2386. PubMed ID: 38664269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group.
    Giani C; Denu RA; Ljevar S; Gronchi A; Napolitano A; Rosenbaum E; Salawu A; Bajpai J; Connolly EA; Lee ATJ; Trent JC; Koseła-Paterczyk H; Chia-Chen Li Z; Ogura K; Palmerini E; Baldi GG; Brunello A; Campos F; Cicala CM; Maki RG; Wagner AJ; Andelkovic V; Loong HH; Wong DD; Jones RL; Tap WD; Taverna SM; Lazar AJ; Demicco EG; Hong A; Bovee JVMG; Dei Tos AP; Fletcher CDM; Baumhoer D; Sbaraglia M; Schaefer IM; Miceli R; Stacchiotti S
    ESMO Open; 2024 Sep; 9(9):103689. PubMed ID: 39265219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant or adjuvant sirolimus for malignant metastatic or locally advanced perivascular epithelioid cell tumors: two case reports.
    Batereau C; Knösel T; Angele M; Dürr HR; D'Anastasi M; Kampmann E; Ismann B; Bücklein V; Lindner LH
    Anticancer Drugs; 2016 Mar; 27(3):254-8. PubMed ID: 26645891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.
    Stacchiotti S; Mir O; Le Cesne A; Vincenzi B; Fedenko A; Maki RG; Somaiah N; Patel S; Brahmi M; Blay JY; Boye K; Sundby Hall K; Gelderblom H; Hindi N; Martin-Broto J; Kosela H; Rutkowski P; Italiano A; Duffaud F; Kobayashi E; Casali PG; Provenzano S; Kawai A
    Oncologist; 2018 Jan; 23(1):62-70. PubMed ID: 28754721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
    Matsumoto K; Onda T; Yaegashi N
    Jpn J Clin Oncol; 2015 May; 45(5):408-10. PubMed ID: 25765457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis.
    Tian W; Ding W; Kim S; Xu X; Pan M; Chen S
    Pancreatology; 2013; 13(4):415-22. PubMed ID: 23890141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.